4YC Stock Chart & Stats
€9.60
€0.22(2.32%)
At close: 4:00 PM EDT
€9.60
€0.22(2.32%)
Day’s Range― - ―
52-Week Range€7.04 - €15.10
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€6.29B
Enterprise Value€1.12M
Total Cash (Recent Filing)€162.17B
Total Debt (Recent Filing)€37.56B
Price to Earnings (P/E)25.0
Beta0.87
Next Earnings
Oct 22, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)68.68
Shares Outstanding679,125,200
10 Day Avg. Volume10
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.66
Price to Sales (P/S)3.09
P/FCF Ratio17.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.65Price Target Upside10.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.42
Revenue Forecast (FY)€2.10B
Bulls Say, Bears Say
Bulls Say
Re-accelerating Revenue GrowthRe-accelerating revenue indicates renewed demand for M3’s healthcare information, marketing, research, and professional-network services. Sustained double-digit growth would support operating scale and reinforce the platform’s relevance to industry clients.
Conservative Balance SheetVery low leverage gives M3 substantial financial flexibility to invest in platforms, technology, and healthcare solutions without heavy debt-service pressure. Growing equity also strengthens resilience if industry conditions or client spending weaken.
Strong Free Cash FlowFree cash flow closely tracking earnings indicates relatively strong earnings quality and internal funding capacity. This supports continued product investment, strategic expansion, and shareholder returns while reducing reliance on external financing.
Bears Say
Margin CompressionThe multi-year decline in margins suggests higher costs or a less favorable business mix. If this persists, revenue growth may translate less effectively into earnings and could limit the long-term scalability of M3’s platform model.
Uneven Operating Cash ConversionOperating cash flow converting below reported earnings points to working-capital or timing drag. Although free cash flow remains strong, persistent weakness in operating conversion could constrain reinvestment capacity and reduce the predictability of cash generation.
Earnings Below Prior PeakThe recovery in net income has not yet restored prior peak earnings power, indicating that growth has not fully offset earlier pressure. This may reflect ongoing margin or mix challenges and leaves less evidence of a complete profitability normalization.
M3 News
4YC FAQ
What was M3 Inc’s price range in the past 12 months?
M3 Inc lowest stock price was €7.04 and its highest was €15.10 in the past 12 months.
What is M3 Inc’s market cap?
M3 Inc’s market cap is €6.29B.
When is M3 Inc’s upcoming earnings report date?
M3 Inc’s upcoming earnings report date is Oct 22, 2026 which is in 57 days.
How were M3 Inc’s earnings last quarter?
M3 Inc released its earnings results on Aug 06, 2026. The company reported €0.073 earnings per share for the quarter, missing the consensus estimate of €0.108 by -€0.035.
Is M3 Inc overvalued?
According to Wall Street analysts M3 Inc’s price is currently Undervalued.
Does M3 Inc pay dividends?
M3 Inc does not currently pay dividends.
What is M3 Inc’s EPS estimate?
M3 Inc’s EPS estimate is 0.1.
How many shares outstanding does M3 Inc have?
M3 Inc has 679,125,200 shares outstanding.
What happened to M3 Inc’s price movement after its last earnings report?
M3 Inc reported an EPS of €0.073 in its last earnings report, missing expectations of €0.108. Following the earnings report the stock price went down -7.013%.
Which hedge fund is a major shareholder of M3 Inc?
Currently, no hedge funds are holding shares in DE:4YC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
M3 Inc
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
4YC Stock 12 Month Forecast
Average Price Target
€10.65
▲(10.95% Upside)